Why high-quality pre-K programs matter

Food Insecurity and the Dangers of Infant Formula Dilution

ConSynance Therapeutics' CSTI-500, an innovative Triple Monoamine Reuptake Inhibitor, has received FDA's Rare Pediatric Disease Designation for treating Prader-Willi Syndrome in children.

January 30th 2023

FDA expands maralixibat label to include PFIC patients aged 12 months and older

Demystifying Infant Formula

Initial approval for maralixibat was granted on March 13, 2024, to treat PFIC patients aged 5 years and older.

October 11th 2022

cUTI Roundtable: The Latest Therapeutic Developments

Joshua Fitch, Senior Editor ;John Parkinson;Morgan Petronelli, Managing Editor

Merck's investigational RSV monoclonal antibody clesrovimab demonstrates positive results

The third and final episode in our series looks at what is in the pipeline as well as a discussion around FDA guidance.

FDA grants RPDD to CSTI-500 for treating pediatric Prader-Willi Syndrome

Merck announced clesrovimab met all primary safety and efficacy endpoints, with additional detailed findings to be presented at an upcoming scientific congress.

Related Content

Celeste Krewson, Assistant Editor

Food Insecurity and the Dangers of Infant Formula Dilution

ConSynance Therapeutics' CSTI-500, an innovative Triple Monoamine Reuptake Inhibitor, has received FDA's Rare Pediatric Disease Designation for treating Prader-Willi Syndrome in children.

January 30th 2023

FDA expands maralixibat label to include PFIC patients aged 12 months and older

Demystifying Infant Formula

Initial approval for maralixibat was granted on March 13, 2024, to treat PFIC patients aged 5 years and older.

October 11th 2022

cUTI Roundtable: The Latest Therapeutic Developments

Joshua Fitch, Senior Editor ;John Parkinson;Morgan Petronelli, Managing Editor

Merck's investigational RSV monoclonal antibody clesrovimab demonstrates positive results

The third and final episode in our series looks at what is in the pipeline as well as a discussion around FDA guidance.